CSL has slashed its earnings and revenue forecasts due to falling US vaccination rates, and shelved plans to demerge its Seqirus vaccines business, sending its shares to fresh six-year lows.
The global biotech giant also faces a vote to remove the entire board at its annual general meeting on Thursday, after shareholders voted against its executive pay report for the second year in a row.
Loading…
